(Oslo, Norway, 15 December 2016)
Reference is made to the stock exchange announcement by Bionor Pharma ASA (now Solon Eiendom ASA) (the «Company», ticker «BIONOR») earlier today regarding a completed extraordinary general meeting of the Company and the stock exchange announcement earlier today regarding completion of the acquisition of the entire share capital of Solon Eiendom AS.
With effect from today, the new Board of Directors of the Company will consist of:
– Simen Thorsen, chairman
– Einar J. Greve, deputy chairman
– Tore Aksel Voldberg, board member
– Bente Bøhler, board member
– Katarina Finneng, board member
The new Board of Directors was elected by the shareholders at the extraordinary general meeting held yesterday, 14 December 2016.
Further, the Board of Directors of the Company has appointed Mr. Andreas Martinussen as the Company’s Chief Executive Officer (CEO) and Mr. Tarjei Røise Warholm as the Company’s Chief Financial Officer (CFO). They will both take over the responsibilities as CEO and CFO as of today.
With effect as of the same date, Unni Hjelmaas will be appointed as CEO of Bionor Immuno AS (a wholly owned subsidiary of the Company).
For further information please contact:
Simen Thorsen (Chairman) email@example.com / 91 886 886
This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.